Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Macular Degeneration Research - Current Award

Photo Pending

Zhenglin Yang, M.D.

University of California, San Diego
La Jolla, CA

Title: Functional Study of HTRA1 and Age-related Macular Degeneration
Non-Technical Title: Etiology and Pathogenesis of Age-related Macular Degeneration

Duration: April 1, 2008 - March 31, 2010
Award Type: Standard
Award Amount: $100,000


Summary:

Identification and functional studies of the HTRA1, a gene that has substantial impact on the risk of AMD, may define key molecular pathways involved in its pathogenesis. The experiments will yield novel mechanistic insights relevant to the pathogenesis of both early and late AMD. This may lead to therapies directed at the underlying cause and pre-symptomatic diagnosis leading to earlier intervention.

Details:

Identification and functional studies of the HTRA1, a gene that has substantial impact on the risk of AMD, may define key molecular pathways involved in its pathogenesis. The experiments will yield novel mechanistic insights relevant to the pathogenesis of both early and late AMD. This may lead to therapies directed at the underlying cause and pre-symptomatic diagnosis leading to earlier intervention.